Lexaria Bioscience Corp. has announced it now holds 60 valid patents granted across major global markets, marking a significant milestone in its intellectual property strategy. The company received six new patents since its last update in October 2025, strengthening its position in key therapeutic areas. The new patents include the company's first Australian patent in its Family #20, covering compositions and methods for sublingual delivery of nicotine, where patents already exist in the United States, Canada, and Japan.
In patent Family #21, focused on compositions and methods for treating hypertension, Lexaria received its first European Union patent, entering what is considered the world's second-largest hypertension market after the United States. For epilepsy treatments in patent Family #24, Lexaria secured two new Australian patents and one European Union patent, bringing its intellectual property in this family to six U.S. patents, four Australian patents, and one European Union patent. The company also received one new U.S. patent in its diabetes-focused Family #27, bringing its total in this family to two U.S. patents, which the company considers important given recent successes in the GLP-1 sector.
Lexaria's patent development process begins with evaluating initial hypotheses through existing scientific literature, followed by animal and human testing to generate data supporting patent applications in international markets. The company emphasizes that granted patents enable safer pursuit of commercial relationships to exploit its innovations. Lexaria's DehydraTECH technology platform improves how various drugs enter the bloodstream through oral delivery, with demonstrated abilities to increase bio-absorption, reduce side effects, and enhance delivery across the blood-brain barrier.
The company maintains a licensed in-house research laboratory and continues to expand its intellectual property portfolio worldwide. Additional information about the company's technology and research is available at https://www.lexariabioscience.com. Separately, the company reminded shareholders to vote in its upcoming annual meeting scheduled for January 27, 2026. Stockholders holding common stock as of December 1, 2025, are eligible to vote, with the company encouraging votes in favor of all proposals. Proxy materials are available online at https://www.colonialstock.com/LEXX2026, where shareholders can vote using their control number. The voting deadline is 4:00 PM PT on January 26, 2026.
